CME Group Cl A had its Relative Strength (RS) Rating upgraded from 70 to 73 Wednesday — a welcome improvement, but still below the 80 or higher score you prefer to see.
IBD's unique RS Rating measures market leadership by showing how a stock's price action over the last 52 weeks compares to that of the other stocks in our database.
History shows that the stocks that go on to make the biggest gains typically have an RS Rating of above 80 as they begin their largest climbs. See if CME Group Cl A can continue to rebound and clear that threshold.
How To Invest In Stocks In Both Bull And Bear Markets
While now is not an ideal time to jump in, see if the stock is able to establish and enter a buy zone in heavy trade.
In terms of fundamentals, the company has posted two quarters of accelerating earnings growth. Top line growth has also moved higher over the same time frame.
The company earns the No. 4 rank among its peers in the Financial Services-Specialty industry group. Marex Group is the No. 1-ranked stock within the group.
RELATED:
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
